title: Second primary melanoma on a patient undergoing vemurafenib therapy. A case report.
abstract: BACKGROUND
  Several side effects have been reported during treatment with vemurafenib, including multiple benign lesions and, less frequently, atypical melanocytic proliferations and second primary melanomas.
  
  
  METHODS
  A 46-year-old man undergoing vemurafenib therapy for metastatic malignant melanoma was clinically and dermoscopically monitored using total-body mapping.
  
  
  RESULTS
  During BRAF inhibitor (BRAFi) treatment, the patient developed atypical melanocytic lesions and particularly secondary primary melanoma.
  
  
  CONCLUSIONS
  Secondary melanomas are usually diagnosed during the early disease stage, and no case of advanced melanomas is reported in the literature, mostly due to careful surveillance in BRAFi-treated patients.
authors.affiliation: Department of Surgical, Microsurgical and Medical Sciences, Dermatology Unit, University of Sassari, ICB-CNR, Sassari, Italy.
authors.forename: Giuliana
authors.initials: G
authors.lastname: Onnis
authors.affiliation: Unit of Cancer Genetics, ICB-CNR, Sassari, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Palmieri
authors.affiliation: Department of Surgical, Microsurgical and Medical Sciences, Dermatology Unit, University of Sassari, ICB-CNR, Sassari, Italy.
authors.forename: Maria Antonietta
authors.initials: MA
authors.lastname: Montesu
authors.affiliation: Department of Surgical, Microsurgical and Medical Sciences, Dermatology Unit, University of Sassari, ICB-CNR, Sassari, Italy.
authors.forename: Rosanna
authors.initials: R
authors.lastname: Satta
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000235:genetics*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D012878:Skin Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf